

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:


PATENT
Attorney Docket No.: 015280-342100US
Client Ref. No.: E-019-98/1
Customer No.: 20350

Attn: Ms. Vonda M. Wallace
Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On May 17, 2004

TOWNSEND and TOWNSEND and CREW LLP

By: Stephanie J. Whitehurst



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

KASLOW *et al.*

Application No.: 09/554,960

Filed: February 12, 2003

For: VACCINES FOR BLOCKING
TRANSMISSION OF *Plasmodium vivax*

Confirmation No. 6829

Examiner: Not yet assigned

Art Unit: Not yet assigned

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

RESPONSE TO NOTIFICATION TO

SATISFY SUPPLEMENTAL FEES

Attn: Ms. Vonda M. Wallace
Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, mailed March 15, 2004, Applicants submit herewith the required paper copy and computer readable copy of the Substitute Sequence Listing.

In response to the request to supply supplemental fees, please note that Applicants responded to this request in their previous Amendment dated December 29, 2003. For further clarification, a copy of the supporting documentation dated December 29, 2003 are provided herewith for your convenience:

1. Copy of Applicants' letter to USPTO clarifying the history of this application (Attachment A); **Please note the international filing date should be December 4, 1998.**
2. Copy of the Transmittal Letter to the US Designated/Elected Office (DO/EO/US) Concerning a Filing Under 35 USC 371 authorizing payment of the outstanding fees in the amount of \$392.00 (Attachment B);
3. Copy of Applicants' Communication Under 37 CFR 1.821-1.825 and Preliminary Amendment dated December 29, 2003 (Attachment C); and
4. Copy of USPTO Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Listing (Attachment D), hereby under response.

Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows. **Amendments to the Specification** begin on page 3 of this paper.

Remarks begin on page 4 of this paper.